Schisandrin B attenuates doxorubicin-induced acute cardiac injury through regulation of metabolites and gut microbiota

Schisandrin B (Sch B), a major bioactive lignan from the medicinal herb Schisandra chinensis, possesses anti-inflammatory and antioxidant properties. However, the mechanism by which it attenuates anthracycline (ANT)-induced acute cardiac injury remains elusive, particularly regarding systemic metabolite dynamics and gut microbiota modulation. Here, we integrate metabolomics with 16 S rDNA high-throughput sequencing to investigate this cardioprotective effect. Our data reveal that Sch B alleviates doxorubicin-induced acute cardiac injury through coordinated regulation of specific metabolic pathways and gut microbial composition. These findings establish a mechanistic basis for the clinical translation of Sch B and provide a framework for further mechanistic dissection of its multi-target actions.